OpenEvidence, a tool that doctors and nurses liken to a medical ChatGPT, plans to announce $200 million in funding at a $6 billion valuation, The New York Times reported.
The new funding comes three months after the startup raised $210 million at a valuation of $3.5 billion, evidence of strong investor interest in industry-specific AI applications.
Trained on the medical journals JAMA and New England Journal of Medicine, the OpenEvidence platform helps users quickly get answers to existing medical knowledge that can help treat patients. Certified healthcare professionals have free access to OpenEvidence’s advertising-supported tools.
OpenEvidence has grown rapidly since its founding in 2022, with the number of clinical consultations per month nearly doubling to 15 million since July, according to the Times.
The round was led by Google Ventures with participation from Sequoia Capital, Kleiner Perkins, Blackstone, Thrive Capital, Coatue Management, Bond, and Craft.
TechCrunch has reached out to OpenEvidence for comment.
tech crunch event
san francisco
|
October 27-29, 2025
